Ibu and Haematotoxicity - a phase IV clinical study of FDA data

Summary:

Haematotoxicity is reported as a side effect among people who take Ibu (ibuprofen), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Gemcitabine, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Haematotoxicity when taking Ibu. It is created by eHealthMe based on reports of 240,078 people who have side effects when taking Ibu from the FDA, and is updated regularly.

What is Ibu?

Ibu has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 246,531 Ibu users. Check the latest studies of Ibu.

What is Haematotoxicity?

Haematotoxicity (toxins that destroy red blood cells) is found to be associated with 343 drugs and 830 conditions by eHealthMe. Check the latest studies of Haematotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

240,078 people reported to have side effects when taking Ibu.
Among them, 35 people (0.01%) have Haematotoxicity.

Among these 35 people:

How long have people been on Ibu when they have Haematotoxicity? *

What is the gender of people who have Haematotoxicity when taking Ibu? *

female: 70 %
male: 30 %

What is the age of people who have Haematotoxicity when taking Ibu? *

What are other drugs people take besides Ibu? *

What are other side effects people have besides Haematotoxicity? *

Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 13 people, 37.14%
Skin Disorder (skin disease): 12 people, 34.29%
Mucosal Inflammation (infection of mucous membrane): 12 people, 34.29%
Muscle Aches (muscle pain): 10 people, 28.57%
Skin Ulcer: 8 people, 22.86%
Hepatotoxicity (chemical-driven liver damage): 8 people, 22.86%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 8 people, 22.86%
Diabetes Mellitus Inadequate Control: 7 people, 20.00%
Hyperglycemia (high blood sugar): 6 people, 17.14%
Neutrophilia: 6 people, 17.14%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 12 people, 34.29%
Muscle Aches (muscle pain): 8 people, 22.86%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 20.00%
Gout (uric acid crystals building up in the body): 7 people, 20.00%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 6 people, 17.14%
Blood Uric Acid Increased: 6 people, 17.14%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 2 people, 5.71%
Breast Cancer: 2 people, 5.71%
Neck Pain: 1 person, 2.86%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Ibu and have Haematotoxicity?

- Check whether Haematotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibu:

Ibu (246,531 reports)

Haematotoxicity treatments and more:

Haematotoxicity (8,984 reports)

Browse all side effects of Ibu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematotoxicity:

Haematotoxicity (343 drugs)

Browse all the conditions that are associated with Haematotoxicity:

Haematotoxicity (830 conditions)

Related publications that referenced our studies

Moslim MA, Sodeman TC, Nawras AT, "A Case of Suggested Ibuprofen-Induced Acute Pancreatitis", American journal of therapeutics, 2016 Nov .
Moslim MA, Sodeman TC, Nawras AT, "A Case of Suggested Ibuprofen-Induced Acute Pancreatitis", American journal of therapeutics, 2016 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on ibuprofen (the active ingredients of Ibu) and Ibu (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.